Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion issues invitation to 2015 Annual General Meeting of Shareholders (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 10 April 2015- Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting will take place on Friday, 8 May 2015 (10:00hrs CEST) at the Congress Center, Messe Basel, Switzerland. At this year's meeting the Board of Directors is proposing an increase in the dividend payment to CHF 1.30 per share. Also, following the approval of the Articles of Association at the 2014 AGM, the Board is proposing for the first time the approval of a maximum compensation for the non-executive members of the Board of Directors and the maximum...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>